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Purpose: The growing burden of cancer and non-
communicable diseases in the developing world is well 
recognized by the WHO and IAEA culminating in a declaration 
of the need to address them by the UN General Assembly in 
2011. It is projected that ~75% of cancer cases will be in Low 
& Lower-Middle Income Countries (LMIC) by 2025. Effective 
solutions require technological and logistical approaches and 
sufficient expertise to establish sustainable capacity and 
capability in country. 
Materials/methods: Recognizing that the essential 
component for any solution requires expertise, the ICEC (1,2) 
was established in 2013 as a not-for-profit non-government 
organization to address the human resources shortage. An 
extensive analysis by the Global Task Force for Radiation for 
Cancer Control under the auspices of the Union for 
International Cancer Control indicates that a solution is both 
possible and economically feasible (3).  
Results: There is a confluence of forces and opportunities 
that makes the solution to what appears to be an 
overwhelming problem one that can and must be addressed. 
This includes: 
a) the necessity for collaboration among existing programs, 
allowing for individual recognition and approaches while 
minimizing competition that can dissuade investment 
b) a cohort of early stage career cancer experts committed 
to global health 
c) participation of the private sector in global cancer 
education and training 
d) success in addressing health disparities in indigenous 
populations in resource-rich countries that is part of global 
cancer care  
e) an influx of retirees seeking opportunities to use their 
skills 
f)  interest in eliminating dangerous nuclear material 
especially in unstable countries 
The ICEC mentorship model is in active organizational and 
funding development. Essential features and challenges are: 
a) establishing a career path with metrics for academic 
advancement so that time, effort and contributions become 
an integral component of a medical career and not an 
extracurricular activity 
b) supporting time and effort in both resource-rich and –poor 
countries 
c) conducting guideline/protocol-based multi-modality 
cancer care at international standards so that LMICs can 
participate fully in research and training 
d) being multi-national from the outset, capitalizing on 
existing twinning programs 
e) creating an essential role for radiation therapy. 
f) incorporating innovations in physics, information 
technology and telecommunications 
Conclusions: The need, opportunity and a path forward for 
reducing the global burden of cancer are in hand. A 
concerted effort and sustainable investment by a broad range 
of partners are essential. The ICEC addresses the sustainable 
human resources problem with catalytic and disruptive 
innovation in cancer care delivery including a career path, 
economics, technology, public-private partnerships as well as 
visionary leaders and investors.  
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Purpose: The aim of this work is to (1) investigate the 
accuracy and robustness of magnitude and phase-derived 
arterial input functions (AIF) as compared to “gold standard” 
volumetric DCE-CT; and (2) evaluate the impact of 
individualized magnitude and phase signal AIF measurements 
on resulting perfusion parameter maps using a common 4D 
temporal dynamic analysis (TDA) method in metastatic brain 
cancer patients treated with stereotactic radiosurgery. 
Methods: We evaluated 14 brain metastases imaged with 
volumetric DCE-CT (Toshiba, Aquilion ONE) and DCE-MRI 
(IMRIS 3T Verio) at baseline then 7 and 21 days post-
radiosurgery.  Both variable-flip-angle (VFA) T1 
measurements and dynamic imaging used 3D-FLASH with 
matched TE/TR of 1.8/4.8ms, with 1x1x5 mm voxels. Voxel-
based whole brain TDA was performed on all data using in-
house software to: (1) compare the AIF curve from DCE-CT 
using the internal carotid artery (AIF) and sagittal sinus (VIF) 
curve from the DCE-CT against DCE-MRI [magnitude (VIFmag) 
and phase-based (VIFph)] (2) compare kinetic parameters 
area under the curve (AUC) and Ktrans, assuming the Modified 
Tofts model when using individual CT AIF, MRI Magnitude and 
Phase-based VIF (Sagittal Sinus) and population-based AIF as 
well as individual voxel-based T10 maps versus assumed T10= 
2400 msec.  
Results: The AUC of individual AIF and VIF on DCE-CT were 
similar and resulting median Ktrans (0.048 +/- 0.03 s-1) was also 
similar. For DCE-MRI, using measured voxel-based T10 maps, 
the resulting Ktrans was higher than for CT using individual 
VIFmag (0.181 +/- 0.11 s-1) or VIFph (0.121 +/- 0.099 s-1). This 
is likely resulting from the smaller AIF peak since the 
population AIF (which more closely resembles CT) correlates 
better to DCE-CT metrics. The measured median T10 value 
was 1572 +/- 594 (n=41) and using the assuming T10=2400 ms 
resulted in significantly higher Ktrans (0.3 +/- 0.14 s-1) and AUC 
(p<0.0006). Voxel-wise correlation between Ktrans values than 
from CT and MRIpopAIF,T10 resulted in high R2 values (~0.5, 
p<0.05) for all imaging days and showed good 
interchangeability (see Bland-Altman plot in Figure 1). 
Conclusion: This preliminary data highlights the stability of 
DCE-CT calculations as well as susceptibility of DCE-MRI Ktrans 
measurements to various imaging factors, including AIF 
selection and T10 values used in the model.  Using the same 
voxel-based analysis platform for both DCE-CT and MR 
significantly improved correlation values confirming the need 
to take into account tumor heterogeneity when assessing 
functional data. 
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